BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 33435584)

  • 1. Real World Analysis of Small Cell Lung Cancer Patients: Prognostic Factors and Treatment Outcomes.
    Moser SS; Bar J; Kan I; Ofek K; Cohen R; Khandelwal N; Shalev V; Chodick G; Siegelmann-Danieli N
    Curr Oncol; 2021 Jan; 28(1):317-331. PubMed ID: 33435584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
    Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
    Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Carboplatin With Cisplatin in Small Cell Lung Cancer in US Veterans.
    Azar I; Yazdanpanah O; Jang H; Austin A; Kim S; Chi J; Alkassis S; Saha BK; Chopra A; Neu K; Mehdi S; Mamdani H
    JAMA Netw Open; 2022 Oct; 5(10):e2237699. PubMed ID: 36264573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [First-line chemotherapy and its survival analysis of 394 patients with extensive-stage small cell lung cancer in a single institute].
    Ma M; Wang M; Xu Y; Hu K; Liu H; Li L; Zhong W; Zhang L; Zhao J; Wang H
    Zhongguo Fei Ai Za Zhi; 2014 Jan; 17(1):8-14. PubMed ID: 24398308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Second-line chemotherapy and its survival analysis of 181 patients with extensive-stage small cell lung cancer in a single institute].
    Ma M; Wang M; Xu Y; Hu K; Liu H; Li L; Zhong W; Zhang L; Zhao J; Wang H
    Zhongguo Fei Ai Za Zhi; 2013 Nov; 16(11):572-8. PubMed ID: 24229622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Correlations between genetic variations of glutathione synthetase gene and the response to platinum-based chemotherapy and prognosis of small cell lung cancer patients].
    Feng T; Li HM; Yuan P; Yu DK; Ma F; Tan WW; Du ZL; Yang J; Huang Y; Lin DX; Xu BH; Tan W
    Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):115-120. PubMed ID: 28219206
    [No Abstract]   [Full Text] [Related]  

  • 7. Prospective Observational Study Evaluating the Prognostic Value of the G8 Screening Tool for Extensive-Stage Small Cell Lung Cancer Patients Who Received Programmed Death-Ligand 1 Inhibitor plus Platinum-Etoposide Chemotherapy.
    Morimoto K; Yamada T; Takeda T; Shiotsu S; Date K; Harada T; Tamiya N; Chihara Y; Takemura Y; Yamada T; Kanda H; Ishida M; Yoshimura A; Iwasaku M; Tokuda S; Kim YH; Takayama K
    Drugs Aging; 2023 Jun; 40(6):563-571. PubMed ID: 37145245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
    Lara PN; Moon J; Redman MW; Semrad TJ; Kelly K; Allen JW; Gitlitz BJ; Mack PC; Gandara DR
    J Thorac Oncol; 2015 Jan; 10(1):110-5. PubMed ID: 25490004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line - Results from the prospective German TLK cohort study.
    Steffens CC; Elender C; Hutzschenreuter U; Dille S; Binninger A; Spring L; Jänicke M; Marschner N;
    Lung Cancer; 2019 Apr; 130():216-225. PubMed ID: 30885347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy versus best supportive care for extensive small cell lung cancer.
    Pelayo Alvarez M; Westeel V; Cortés-Jofré M; Bonfill Cosp X
    Cochrane Database Syst Rev; 2013 Nov; (11):CD001990. PubMed ID: 24282143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment beyond four cycles of first line Platinum and Etoposide chemotherapy in real-life patients with stage IV Small Cell Lung Cancer: a retrospective study of the Merseyside and Cheshire Cancer network.
    Sallam M; Wong H; Escriu C
    BMC Pulm Med; 2019 Nov; 19(1):195. PubMed ID: 31675940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Genetic variation in DNA polymerase kappa gene is associated with the prognosis after platinum-based chemotherapy in small cell lung cancer patients].
    Chen JN; Feng T; Yang J; Li HM; Yuan P; Ma F; Yin LL; Lin DX; Xu BH; Tan W
    Zhonghua Zhong Liu Za Zhi; 2019 Feb; 41(2):112-117. PubMed ID: 30862140
    [No Abstract]   [Full Text] [Related]  

  • 13. Platinum versus non-platinum chemotherapy regimens for small cell lung cancer.
    Amarasena IU; Chatterjee S; Walters JA; Wood-Baker R; Fong KM
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD006849. PubMed ID: 26233609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.
    Reck M; Luft A; Szczesna A; Havel L; Kim SW; Akerley W; Pietanza MC; Wu YL; Zielinski C; Thomas M; Felip E; Gold K; Horn L; Aerts J; Nakagawa K; Lorigan P; Pieters A; Kong Sanchez T; Fairchild J; Spigel D
    J Clin Oncol; 2016 Nov; 34(31):3740-3748. PubMed ID: 27458307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoimmunotherapy as the First-Line Treatment for Patients With Extensive-Stage Small-Cell Lung Cancer and an ECOG Performance Status 2 or 3.
    Agarwal M; Liu A; Langlais BT; Leventakos K; Yu NY; Almquist D; Manochakian R; Ernani V
    Clin Lung Cancer; 2023 Nov; 24(7):591-597. PubMed ID: 37365076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
    Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
    Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
    Reck M; Thatcher N; Smit EF; Lorigan P; Szutowicz-Zielinska E; Liepa AM; Winfree KB; Peterson P; Guba SC; Socinski MA
    Lung Cancer; 2012 Dec; 78(3):276-81. PubMed ID: 23043970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FRESC: French Real world Extensive stage SCLC Cohorts: A retrospective study on patient characteristics and treatment strategy based on KBP-2010.
    Debieuvre D; Dayen C; Dixmier A; Pau D; Sibley-Revelat A; Greenwood W; Gally S; Falchero L
    Lung Cancer; 2022 Feb; 164():1-7. PubMed ID: 34954472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rechallenge treatment with a platinum-based regimen in patients with sensitive relapsed small-cell lung cancer.
    Naito Y; Yamada K; Imamura Y; Ishii H; Matsuo N; Tokito T; Kinoshita T; Azuma K; Hoshino T
    Med Oncol; 2018 Apr; 35(5):61. PubMed ID: 29610997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small-cell lung cancer patients treated with first-line platinum-containing chemotherapy.
    He M; Chi X; Shi X; Sun Y; Yang X; Wang L; Wang B; Li H
    Thorac Cancer; 2021 Dec; 12(23):3101-3109. PubMed ID: 34725930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.